Results 41 to 50 of about 3,791 (213)

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumors. [PDF]

J Nucl Med
Visual Abstract This study investigates the radiobiology of peptide receptor radionuclide therapy (PRRT) using clinically relevant cancer cell lines by developing a framework for realistic cellular dosimetry in 2- and 3-dimensional cluster-forming ...
Tamborino G, Engbers P, de Wolf TH, Reuvers TGA, Verhagen R, Konijnenberg M, Nonnekens J.   +6 more
europepmc   +2 more sources

Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review

World Journal of Nuclear Medicine, 2021
Neuroendocrine neoplasms (NENs) are a very diverse group of tumors with a worldwide rise in incidence. Systemic therapy remains the mainstay treatment for unresectable and/or metastatic NENs.
Thuan Koh, Eva Bezak, David Chan, Gabrielle Cehic   +3 more
doaj   +1 more source

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

Trials, 2020
Background Lutetium-177-DOTA-octreotate (177Lu-DOTATATE) significantly increases survival and response rates in patients with grade I and grade II neuroendocrine tumors (NETs). However, survival and response rates are significantly lower in patients with
Sander C. Ebbers, Arthur J. A. T. Braat, Adriaan Moelker, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Maarten W. Barentsz   +5 more
doaj   +1 more source

Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE

Frontiers in Endocrinology, 2022
We describe a 96-year-old man with insulin-dependent type 2 diabetes mellitus who, despite insulin cessation, presented with recurrent hypoglycemia associated with confirmed inappropriate endogenous hyperinsulinemia.
Shejil Kumar, Mariah Melek, Peter Rohl
doaj   +1 more source

Evaluation of using small volume of interest regions for clinical kidney dosimetry in ¹⁷⁷Lu-DOTATATE treatments. [PDF]

EJNMMI Phys
Segmentation of the whole-kidney parenchyma (WKP) is considered the reference method for kidney dosimetry of radiopharmaceuticals, as it provides the average absorbed dose to the fully delineated WKP.
Khan J, Rydèn T, Van Essen M, Svensson J, Bernhardt P.   +4 more
europepmc   +2 more sources

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu

EJNMMI Radiopharmacy and Chemistry, 2019
Background In this work, a lutetium-177 (177Lu) production method based on the separation of nuclear isomers, 177mLu & 177Lu, is reported. The 177mLu-177Lu separation is performed by combining the use of DOTA & DOTA-labelled peptide (DOTATATE) and liquid-
Rupali Bhardwaj, Hubert Th. Wolterbeek, Antonia G. Denkova, Pablo Serra-Crespo   +3 more
doaj   +1 more source

P09.05 177Lu-DOTATATE therapy in progressive meningioma

Neuro-Oncology, 2019
Abstract BACKGROUND Progressive meningioma is a challenging condition with a decreasing number of treatment options over the course of disease. Neurovascular involvement and multifocal disease often complicate surgical management. In addition, repeated radiotherapy carriers a risk of side effects.
M Müther, W Roll, B Zinnhardt, M Schäfers, K Rahbar, B Brokinkel, W Stummer   +6 more
openaire   +2 more sources

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

Cancers, 2022
Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Morticia N Becx, N. Minczeles, T. Brabander, W. D. de Herder, J. Nonnekens, J. Hofland   +5 more
semanticscholar   +1 more source

Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in patients and clinically realistic simulations

EJNMMI Research, 2023
Background Dosimetry promises many advantages for radiopharmaceutical therapies but repeat post-therapy imaging for dosimetry can burden both patients and clinics.
Avery B. Peterson, David M Mirando, Y. Dewaraja   +2 more
semanticscholar   +1 more source

Somatostatin Receptor Theranostics for Refractory Meningiomas

Current Oncology, 2022
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy.
Betty Salgues, Thomas Graillon, Tatiana Horowitz, Olivier Chinot, Laetitia Padovani, David Taïeb, Eric Guedj   +6 more
doaj   +1 more source